Precision medicine at Memorial Sloan Kettering Cancer Center: Clinical next-generation sequencing enabling next-generation targeted therapy trials

Drug Discovery Today

Volumn 20, Issue 12, 2015, Pages 1422-1428

  Hyman, David M ^a,b   Solit, David B ^a,b   Arcila, Maria E ^a   Cheng, Donavan T ^a   Sabbatini, Paul ^a,b   Baselga, Jose ^a,b   Berger, Michael F ^a,b   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CENTER; CLINICAL RESEARCH; EXOME; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HUMAN; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; REVIEW; SOLID TUMOR; SOMATIC MUTATION; CLINICAL TRIAL (TOPIC); GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES;

CLINICAL TRIALS AS TOPIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; PRECISION MEDICINE;

EID: 84949536487     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.08.005     Document Type: Short Survey

References (20)

1. D.J. Slamon, and et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
2. S.M. Swain, and et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer N. Engl. J. Med. 372 2015 724 734
3. P.B. Chapman, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
4. C. Zhou, and et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol. 12 2011 735 742
5. A.T. Shaw, and et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N. Engl. J. Med. 368 2013 2385 2394
6. A.T. Shaw, and et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer N. Engl. J. Med. 371 2014 1963 1971
7. G.D. Demetri, and et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
8. F.S. Collins, and H. Varmus A new initiative on precision medicine N. Engl. J. Med. 372 2015 793 795
9. H.H. Won, and et al. Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing J. Vis. Exp. 80 2013 e50710
10. D.T. Cheng, and et al. MSK-IMPACT: a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology J. Mol. Diagn. 2015 10.1016/j.jmoldx.2014.12.006
11. Z. Zheng, and et al. Anchored multiplex PCR for targeted next-generation sequencing Nat. Med. 20 2014 1479 1484
12. Y.M. Wu, and et al. Identification of targetable FGFR gene fusions in diverse cancers Cancer Discov. 3 2013 636 647
13. R.C. Green, and et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing Genet. Med. 15 2013 565 574
14. D.V. Catenacci, and et al. Tumor genome analysis includes germline genome: are we ready for surprises? Int. J. Cancer 136 2015 1559 1567
15. L. Busque, and et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis Nat. Genet. 44 2012 1179 1181
16. S. Jaiswal, and et al. Age-related clonal hematopoiesis associated with adverse outcomes N. Engl. J. Med. 371 2014 2488 2498
17. M. Xie, and et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies Nat. Med. 20 2014 1472 1478
18. E. Cerami, and et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Cancer Discov. 2 2012 401 404
19. J. Gao, and et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci. Signal. 6 2013 pl1
20. P.K. Paik, and et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping Cancer Discov. 5 2015 842 849